海翔药业：公司的对外投资项目均结合当时自身的情况、市场环境

Group 1 - The company, Haixiang Pharmaceutical (002099), responded to investor inquiries on February 3, indicating that its external investment projects are made based on its own circumstances and market environment for healthy development [1] - The company emphasizes that all investment projects strictly adhere to relevant laws and regulations, fulfilling necessary approval procedures and disclosure obligations [1]